Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Successful Unrelated Bone Marrow Transplantation for Three patients with Amegakaryocytic Thrombocytopenia with Radio-Ulnar Synostosis (CTRUS) in Japan

Yoshitoshi Ohtsuka, MD, PhD

Blood (2011) 118 (21): 4510.

https://doi.org/10.1182/blood.V118.21.4510.4510

Published: 2011

Journal Articles

Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations

Blood (2007) 109 (12): 5477–5480.

https://doi.org/10.1182/blood-2006-09-046649

Published: 2007

Journal Articles

Immunosuppressive Therapy in Children with Refractory Anemia: Results of Japanese Childhood MDS Study Group Trial (MDS99).

Daisuke Hasegawa, MD, Hiroshi Yagasaki, MD, Yoshitoshi Ohtsuka, MD, Masami Inoue, MD, Akira Kikuchi, MD, Akira Ohara, MD, Masahiro Tsuchida, MD, Seiji Kojima, MD, Atsushi Manabe, MD, Tatsutoshi Nakahata, MD

Blood (2006) 108 (11): 2674.

https://doi.org/10.1182/blood.V108.11.2674.2674

Published: 2006

Journal Articles

RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro

Yoshitoshi Ohtsuka, Atsushi Manabe, Hirohide Kawasaki, Daisuke Hasegawa, Yuji Zaike, Sumiko Watanabe, Takakuni Tanizawa, Tatsutoshi Nakahata, Kohichiro Tsuji

Blood (2005) 106 (9): 3134–3141.

https://doi.org/10.1182/blood-2005-03-0972

Published: 2005

Journal Articles

Bisphosphonate Zoledronic Acid (ZOL) Inhibits the Abnormal Proliferation and Differentiation of Juvenile Myelomonocytic Leukemia (JMML) Cells.

Yoshitoshi Ohtsuka, MD, Atsushi Manabe, MD, Hirohide Kawasaki, MD, Sumiko Watanabe, MD, Yuji Zaike, Daisuke Hasegawa, MD, Toshiyasu Miyazaki, Takakuni Tanizawa, MD, Tatsutoshi Nakahata, MD, Kohichiro Tsuji, MD

Blood (2004) 104 (11): 4725.

https://doi.org/10.1182/blood.V104.11.4725.4725

Published: 2004

Journal Articles

Acute Myeloid Leukemia (AML) - Type Chemotherapy for Newly Diagnosed Children with Myelodysplastic Syndrome (MDS): A Japanese Childhood MDS Study Group Trial MDS99.

Yoshitoshi Ohtsuka, MD, Atsushi Manabe, MD, Jun Okamura, MD, Seiji Kojima, MD, Akira Ohara, MD, Masahiro Tuchida, MD, Koichiro Ikuta, MD, Shigeyoshi Hibi, MD, Keisei Kawa, MD, Miharu Yabe, MD, Arata Watanabe, MD, Kazuhiro Ueda, MD, Shinpei Nakazawa, MD, Sumio Miyazaki, MD, Tatsutoshi Nakahata, MD

Blood (2004) 104 (11): 4726.

https://doi.org/10.1182/blood.V104.11.4726.4726

Published: 2004

NARROW

Successful Unrelated Bone Marrow Transplantation for Three patients with Amegakaryocytic Thrombocytopenia with Radio-Ulnar Synostosis (CTRUS) in Japan

Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations

Immunosuppressive Therapy in Children with Refractory Anemia: Results of Japanese Childhood MDS Study Group Trial (MDS99).

RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro

Bisphosphonate Zoledronic Acid (ZOL) Inhibits the Abnormal Proliferation and Differentiation of Juvenile Myelomonocytic Leukemia (JMML) Cells.

Acute Myeloid Leukemia (AML) - Type Chemotherapy for Newly Diagnosed Children with Myelodysplastic Syndrome (MDS): A Japanese Childhood MDS Study Group Trial MDS99.

Email alerts

ASH Publications

American Society of Hematology

Successful Unrelated Bone Marrow Transplantation for Three patients with Amegakaryocytic Thrombocytopenia with Radio-Ulnar Synostosis (CTRUS) in Japan

Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations

Immunosuppressive Therapy in Children with Refractory Anemia: Results of Japanese Childhood MDS Study Group Trial (MDS99).

RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro

Bisphosphonate Zoledronic Acid (ZOL) Inhibits the Abnormal Proliferation and Differentiation of Juvenile Myelomonocytic Leukemia (JMML) Cells.

Acute Myeloid Leukemia (AML) - Type Chemotherapy for Newly Diagnosed Children with Myelodysplastic Syndrome (MDS): A Japanese Childhood MDS Study Group Trial MDS99.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only